Titan Pharma (TTNP) |
|
3.45 -0.06 (-1.71%)
|
02-25 12:07 |
|
Open: |
3.48 |
Pre. Close: |
3.51 |
|
High:
|
3.77 |
Low:
|
3.41 |
|
Volume:
|
950,087 |
Market Cap:
|
34M |
|
|
|
|
Titan Pharmaceuticals, Inc., a pharmaceutical company, develops therapeutics for the treatment of chronic diseases. It develops products based on ProNeura, a proprietary long-term drug delivery platform that focuses primarily on the treatment for chronic diseases. The company also develops ProNeura-Ropinirole, an implant to provide delivery of ropinirole, a dopamine agonist for the treatment of Parkinson's disease; and triiodothyronine, an implant for the treatment of hypothyroidism. Titan Pharmaceuticals, Inc. was incorporated in 1992 and is based in South San Francisco, California. |
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
3.582 - 3.603 |
3.603 - 3.624 |
|
Low:
|
3.311 - 3.335 |
3.335 - 3.359 |
|
Close:
|
3.471 - 3.508 |
3.508 - 3.544 |
|
Technical analysis |
as of: 2021-02-25 11:51:56 AM |
|
Overall:
|
  |
| Stoxline posted a NEUTRAL today, upgraded from lower rating. Current trend continues, but could change at anytime. It is not a good time to buy or sell. |
| Target: |
Six months: 4.71 One year: 5.38 |
| Support: |
Support1: 3.10 Support2: 2.58 |
| Resistance: |
Resistance1: 4.03 Resistance2: 4.61 |
| Pivot: |
3.77 |
| Moving Average: |
MA(5): 3.61  MA(20): 3.65
MA(100): 3.78 MA(250): 6.36 |
| MACD: |
MACD(12,26): 0.05 Signal(9): 0.09 |
| Stochastic oscillator: |
%K(14,3): 21.00 %D(3): 27.72 |
| RSI: |
RSI(14): 48.00 |
| 52-week: |
High: 16.50 Low: 2.70 Change(%): -55.0 |
| Average Vol(K): |
3-Month: 455971 10-Days: 255332 |
|
Price, moving averages and Bollinger Bands |
|
Price and moving averages has closed below its Short term moving average. Short term moving average is currently above mid-term; AND below long term moving averages. From the relationship between price and moving averages; we can see that: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.TTNP has closed above bottom band by 23.1%. Bollinger Bands are 41% narrower than normal. The narrow width of the bands suggests low volatility as compared to TTNP's normal range. The bands have been in this narrow range for 0 bars. This is a sign that the market may be about to initiate a new trend. |
|
|
Headline News |
Wed, 24 Feb 2021
Titan Pharmaceuticals Inc. (TTNP) Soars 4.78% on February 24 - Equities.com
Thu, 18 Feb 2021
Titan Pharmaceuticals Inc. (TTNP) Soars 14.37% on February 18 - Equities.com
Fri, 12 Feb 2021
Titan Pharmaceuticals Inc. (TTNP) Soars 3.39% on February 12 - Equities.com
Wed, 10 Feb 2021
Should You Buy Titan Pharmaceuticals, Inc. common stock (TTNP) Stock on Wednesday? - InvestorsObserver
Tue, 09 Feb 2021
Titan Pharmaceuticals Inc. (TTNP) Soars 8.74% on February 09 - Equities.com
Mon, 08 Feb 2021
Titan Pharmaceuticals Inc. (TTNP) Soars 6.58% on February 08 - Equities.com
|
Financial Analysis |
| Growth |
 |
| Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing. |
| Profitability |
 |
| Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs. |
| Solvency |
|
| Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry. |
| Efficiency |
 |
| Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not. |
| Price to Book Value: |
Underperform |
Discounted cash flow: |
Outperform |
| Return on Assets: |
Underperform |
Price to Earnings: |
Underperform |
| Return on Equity: |
Outperform |
Debt to Equity: |
Underperform |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. (M) |
10 |
| Shares Float (M) |
5 |
|
% Held by Insiders
|
5.08 |
|
% Held by Institutions
|
3.53 |
|
Shares Short (K)
|
510 |
|
Shares Short P. Month (K)
|
835 |
Stock Financials |
|
EPS
|
-7.077 |
|
EPS Est This Year
|
|
|
EPS Est Next Year
|
|
|
Book Value (p.s.)
|
-0.230 |
|
Profit Margin
|
|
|
Operating Margin
|
-341.68 |
|
Return on Assets (ttm)
|
-160.2 |
|
Return on Equity (ttm)
|
|
|
Qtrly Rev. Growth
|
18.3 |
|
Gross Profit (p.s.)
|
-0.499 |
|
Sales Per Share
|
0.507 |
|
EBITDA (p.s.)
|
-1.703 |
|
Qtrly Earnings Growth
|
|
|
Operating Cash Flow (M)
|
-16 |
|
Levered Free Cash Flow (M)
|
-11 |
Stock Valuations |
|
PE Ratio
|
-0.50 |
|
PEG Ratio
|
|
|
Price to Book value
|
-15.26 |
|
Price to Sales
|
6.92 |
|
Price to Cash Flow
|
-2.12 |
Stock Dividends |
|
Dividend
|
|
|
Forward Dividend
|
|
|
Dividend Yield
|
|
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
7 Binary Options
|
|
Your Ad Here
|
|
